Ares Management Corporation · ARES · FY2026 Q2 · Calendar Q3 2026
ARES Q2: Record fundraising supports continued fee-related growth
The quarter supports a constructive earnings-growth case: record fundraising, expanding fee-related earnings and durable institutional demand improve the setup for future fee-paying AUM growth. The thesis still depends on deployment, wealth-channel stabilization and successful integration of acquisitions.
Research this report with FN2. Free to start; review your question before sending.
Earnings scorecard
Reported versus consensusMarket reaction
prior-close to event-session closeAsk FN2 about ARES FY2026 Q2
Choose a question to continue your researchFree to start. Your question opens in chat for you to review and send. FN2 can look up the transcript, financials and prior quarters.
Transcript intelligence
What changed
Compared with the prior quarter, fundraising increased from a record $30 billion to $36 billion, AUM reached $671 billion, and management highlighted accelerating institutional private-credit demand alongside stabilized wealth outflows. New product launches and acquisitions broadened the platform, while AI and technology investment became a more explicit efficiency priority.
Guidance delta
Management maintained its outlook and targeted the upper end of the 0–150 basis-point margin-expansion range.
Key takeaways
- Management reported record Q2 fundraising of $36 billion and $170 billion of dry powder.
- Fee-related earnings rose 20%, while fee-paying AUM in the insurance franchise grew 54% year over year.
- Institutional private-credit demand accelerated and wealth-channel outflows stabilized, but deployment and redemption trends remain important variables.
Management priorities
- Scale private-credit, infrastructure, insurance and wealth-management products.
- Advance Evergreen Core, European direct lending, Japan Industrial Development and infrastructure-debt funds.
- Use acquisitions, technology and AI integration to expand capabilities and improve efficiency.
Follow ARES with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Analyst 52W Price Targets
Latest persisted target per named analyst; persisted previous close from FN2's market snapshot as of Nov 16, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Wells Fargo | Overweight | Overweight | Maintain | Oct 30, 2026 |
| TD Cowen | Buy | Buy | Maintain | Oct 30, 2026 |
| RBC Capital | Outperform | Outperform | Maintain | Oct 30, 2026 |
| Keefe, Bruyette & Woods | Market Perform | Market Perform | Maintain | Oct 30, 2026 |
| JP Morgan | Overweight | Overweight | Maintain | Oct 30, 2026 |
| Barclays | Overweight | Overweight | Maintain | Oct 30, 2026 |
| BMO Capital | Market Perform | Market Perform | Maintain | Oct 27, 2026 |
| Piper Sandler | Overweight | Overweight | Maintain | Oct 19, 2026 |
| UBS | Neutral | Neutral | Maintain | Oct 13, 2026 |
| Oppenheimer | Outperform | Outperform | Maintain | Aug 27, 2026 |
| Citizens | Market Outperform | Market Outperform | Maintain | Jul 9, 2026 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | Apr 21, 2026 |
| Goldman Sachs | Buy | Buy | Maintain | Apr 7, 2026 |
| Raymond James | Strong Buy | Market Perform | Upgrade | Feb 9, 2026 |
| Deutsche Bank | Buy | Hold | Upgrade | Feb 9, 2026 |
| B of A Securities | Buy | Buy | Maintain | Oct 3, 2025 |
| JMP Securities | Market Outperform | Market Outperform | Maintain | Aug 6, 2025 |
| Jefferies | Hold | Hold | Maintain | May 9, 2024 |
| SunTrust Robinson Humphrey | Buy | Buy | Maintain | Nov 25, 2020 |
| Keefe Bruyette & Woods | Outperform | Outperform | Maintain | Nov 25, 2020 |
| Credit Suisse | Outperform | Neutral | Upgrade | Nov 25, 2020 |
| Bank of America | Buy | Neutral | Upgrade | Nov 25, 2020 |
Named analyst price targets
Upside is calculated against the persisted previous close $134.61. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Citizens | Devin Ryan | $160 | $128.15 | +18.9% | Oct 30, 2026 |
| BMO Capital | Analyst unavailable | $130 | $121.76 | -3.4% | Oct 27, 2026 |
| Morgan Stanley | Analyst unavailable | $149 | $114.65 | +10.7% | Oct 16, 2026 |
| Wells Fargo | Daniel Welden | $136 | $116.57 | +1.0% | Oct 1, 2026 |
| Piper Sandler | Crispin Love | $150 | $121.48 | +11.4% | Sep 24, 2026 |
| RBC Capital | Bart Dziarski | $168 | $134.39 | +24.8% | Aug 3, 2026 |
| Deutsche Bank | Analyst unavailable | $144 | $135.01 | +7.0% | Aug 3, 2026 |
| Oppenheimer | Analyst unavailable | $151 | $133.2 | +12.2% | Aug 3, 2026 |
| BMO Capital | Brennan Hawken | $134 | $128.09 | -0.5% | Aug 3, 2026 |
| Morgan Stanley | Analyst unavailable | $160 | $121.14 | +18.9% | Jul 21, 2026 |
| BMO Capital | Analyst unavailable | $128 | $122.06 | -4.9% | Jul 13, 2026 |
| Barclays | Analyst unavailable | $139 | $120.29 | +3.3% | Jul 9, 2026 |
| Barclays | Analyst unavailable | $140 | $119.06 | +4.0% | May 4, 2026 |
| Morgan Stanley | Analyst unavailable | $163 | $122.32 | +21.1% | Apr 21, 2026 |
| RBC Capital | Bart Dziarski | $173 | $115.94 | +28.5% | Feb 24, 2026 |
| UBS | Analyst unavailable | $148 | $128.16 | +9.9% | Feb 20, 2026 |
| RBC Capital | Analyst unavailable | $180 | $135.12 | +33.7% | Feb 9, 2026 |
| Oppenheimer | Analyst unavailable | $215 | $128.94 | +59.7% | Feb 6, 2026 |
| Goldman Sachs | Analyst unavailable | $165 | $128.7 | +22.6% | Feb 6, 2026 |
| Barclays | Analyst unavailable | $190 | $121.87 | +41.1% | Feb 6, 2026 |
| Deutsche Bank | Brian Bedell | $155 | $121.87 | +15.1% | Feb 6, 2026 |
| Morgan Stanley | Analyst unavailable | $178 | $149.69 | +32.2% | Jan 27, 2026 |
| Oppenheimer | Analyst unavailable | $224 | $167.03 | +66.4% | Jan 20, 2026 |
| UBS | Analyst unavailable | $198 | $169.5 | +47.1% | Jan 13, 2026 |
| Barclays | Analyst unavailable | $222 | $175.75 | +64.9% | Jan 9, 2026 |
| Wolfe Research | Analyst unavailable | $210 | $172.84 | +56.0% | Jan 7, 2026 |
| Barclays | Analyst unavailable | $218 | $176.82 | +61.9% | Dec 12, 2025 |
| UBS | Michael Brown | $201 | $178.3 | +49.3% | Dec 11, 2025 |
| Oppenheimer | Chris Kotowski | $190 | $153.75 | +41.1% | Nov 4, 2025 |
| Morgan Stanley | Analyst unavailable | $175 | $149.21 | +30.0% | Oct 21, 2025 |
| Oppenheimer | Analyst unavailable | $180 | $143.63 | +33.7% | Oct 14, 2025 |
| Barclays | Analyst unavailable | $187 | $148.64 | +38.9% | Oct 8, 2025 |
| JMP Securities | Brian McKenna | $195 | $180.34 | +44.9% | Jul 14, 2025 |
| Wolfe Research | Steven Chubak | $193 | $159.63 | +43.4% | May 6, 2025 |
| Barclays | Benjamin Budish | $182 | $160.96 | +35.2% | May 6, 2025 |
| Wolfe Research | Steven Chubak | $218 | $180.87 | +61.9% | Jan 3, 2025 |
| RBC Capital | Kenneth Lee | $205 | $176.11 | +52.3% | Dec 10, 2024 |
| RBC Capital | Kenneth Lee | $170 | $157.81 | +26.3% | Oct 11, 2024 |
| Morgan Stanley | Michael Cyprys | $162 | $156.95 | +20.3% | Oct 10, 2024 |
| Barclays | Benjamin Budish | $174 | $160.39 | +29.3% | Oct 7, 2024 |
| CFRA | Kenneth Leon | $170 | $156.38 | +26.3% | Sep 23, 2024 |
| Wells Fargo | Michael Brown | $156 | $141.46 | +15.9% | Sep 11, 2024 |
| Redburn Partners | Nicholas Watts | $140 | $146.96 | +4.0% | Aug 27, 2024 |
| Barclays | Benjamin Budish | $155 | $139.26 | +15.1% | Aug 5, 2024 |
| CFRA | Kenneth Leon | $155 | $139.26 | +15.1% | Aug 2, 2024 |
| Barclays | Benjamin Budish | $151 | $134.78 | +12.2% | Jul 10, 2024 |
| Deutsche Bank | Brian Bedell | $132 | $137.49 | -1.9% | Jun 13, 2024 |
| Deutsche Bank | Brian Bedell | $176 | $146.7 | +30.7% | May 28, 2024 |
| UBS | Brent Dilts | $160 | $146.31 | +18.9% | May 22, 2024 |
| RBC Capital | Kenneth Lee | $150 | $136.17 | +11.4% | May 7, 2024 |
| Barclays | Benjamin Budish | $150 | $134.64 | +11.4% | May 3, 2024 |
| Barclays | Analyst unavailable | $87 | $75.1 | -35.4% | Jan 12, 2023 |
| Barclays | Analyst unavailable | $82 | $68.14 | -39.1% | Dec 19, 2022 |
| UBS | Analyst unavailable | $95 | $79.53 | -29.4% | Nov 15, 2022 |
| BMO Capital | Analyst unavailable | $87 | $68.79 | -35.4% | Apr 29, 2022 |
| Morgan Stanley | Analyst unavailable | $90 | $81.94 | -33.1% | Apr 20, 2022 |
| Wells Fargo | Analyst unavailable | $92 | $79.71 | -31.7% | Apr 19, 2022 |
| Barclays | Jeremy Campbell | $62 | $53.55 | -53.9% | Apr 12, 2021 |
Track every rating change on ARES the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationAres Management Corporation functions as an investment firm specializing in alternative assets, with operations spanning the United States, Europe, and Asia. Its Tradable Credit division oversees diverse investment vehicles, including pooled funds and separately managed accounts for institutional investors, alongside publicly traded products and sub-advised funds aimed at retail investors, all within the tradable and non-investment grade corporate credit markets. The Direct Lending segment delivers financial solutions to small and medium-sized businesses.…
Historical context
All ARES earningsFinancial Services peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| BN Brookfield Corporation | FY2026 Q3 · Calendar Q4 2026 | -6.1% | -1.0% | Brookfield’s Q3 earnings rose as fundraising and Wealth Solutions gained traction |
| NU Nu Holdings Ltd. | FY2026 Q3 · Calendar Q4 2026 | -2.8% | -4.0% | Nu reports record Q3 revenue as credit and international expansion grow |
| BAP Credicorp Ltd. | FY2026 Q3 · Calendar Q4 2026 | -2.6% | +3.3% | Credicorp maintains 2026 guidance as lending and fee growth meet El Niño risks |
| CIB Grupo Cibest S.A. | FY2026 Q3 · Calendar Q4 2026 | -10.1% | -4.0% | Grupo Cibest raises loan-growth outlook as commercial lending and Nequi underpin Q3 |
| MGRE Affiliated Managers Group, Inc. | FY2026 Q3 · Calendar Q4 2026 | +8.1% | +0.6% | AMG: Alternatives drive record Q3 as firm maintains Q4 outlook |
| MGRD Affiliated Managers Group, Inc. | FY2026 Q3 · Calendar Q4 2026 | +8.1% | +1.4% | AMG’s Q3 Growth Centers on Alternatives, Inflows and Buybacks |
Latest beats and misses
Who reports nextBeat on EPS
- NBISFY2026 Q3 · November 12, 2026+141.5% EPS-16.8% move
- AMATFY2026 Q4 · November 12, 2026+2.5% EPS-3.6% move
- CSCOFY2027 Q1 · November 12, 2026+5.3% EPS+1.2% move
- ASNDFY2026 Q3 · November 12, 2026+38.7% EPS+3.0% move
- TTEKFY2026 Q4 · November 11, 2026+4.6% EPS+4.8% move
- CTA-PAFY2026 Q3 · July 31, 2026+232.7% EPS— move
Missed on EPS
- ECFY2026 Q3 · November 12, 2026-5.6% EPS+0.7% move
- CBRSFY2026 Q3 · November 12, 2026-333.5% EPS-3.3% move
- BNFY2026 Q3 · November 12, 2026-6.1% EPS-1.0% move
- NUFY2026 Q3 · November 12, 2026-2.8% EPS-4.0% move
- PBRFY2026 Q3 · November 10, 2026-13.0% EPS-2.5% move
- EMBJFY2026 Q3 · November 10, 2026-49.4% EPS+7.0% move
Get the ARES recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-07-31T19:08:03.618314+00:00
- FN2 earnings calendar · 2026-09-05T01:23:14.965082+00:00
- Polygon adjusted daily market bars · 2026-09-23T06:10:55.039911+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-09-23T06:10:55.036811+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-09-23. For educational purposes only; not investment advice.